Patient case: 52-year-old male with Colon cancer. Genetic variant: KRAS (G13D), BRAF (V600E). Other conditions: Type II Diabetes, Hypertension.

Clinical trial: Combination Chemotherapy in Treating Patients With Colon Cancer

Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which schedule of chemotherapy is most effective in treating colon cancer.
  PURPOSE: Randomized phase III trial to compare different schedules of chemotherapy using carboplatin with fluorouracil and leucovorin in treating patients who have stage IIB or stage III colon cancer.

Detailed description: OBJECTIVES:
  -  Compare the disease-free survival of patients with completely resected stage IIB or III colon cancer treated with adjuvant chronomodulated vs standard schedule fluorouracil and leucovorin calcium with or without carboplatin.
  -  Compare the overall survival of patients treated with these regimens.
  -  Compare the toxicity of these regimens in these patients.
  -  Compare the quality of life of patients treated with these regimens.
  -  Determine the dose intensities of fluorouracil and carboplatin in these patients.
  OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and disease stage (IIB vs III). Patients are randomized to 1 of 4 treatment arms.
  -  Arm I (standard schedule): Patients receive fluorouracil (5-FU) IV continuously and leucovorin calcium (CF) IV on days 1 and 2.
  -  Arm II (standard + carboplatin schedule): Patients receive 5-FU and CF as in arm I plus carboplatin IV on day 1.
  -  Arm III (chronomodulated schedule): Patients receive 5-FU IV continuously and CF IV continuously on days 1-4.
  -  Arm IV (chronomodulated + carboplatin schedule): Patients receive 5-FU and CF as in arm III plus carboplatin IV continuously on days 1-4.
  Quality of life is assessed.
  Treatment in all arms repeats every 14 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.
  PROJECTED ACCRUAL: A total of 660-800 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically confirmed adenocarcinoma of the colon
  -  Stage IIB or III (Dukes stage B2 or C)
  -  Complete curative resection performed within the past 7 weeks (negative margins)
  -  No local or regional relapsed disease
  -  Tumor more than 15 cm above the anal margin
  -  Carcinoembryonic antigen less than 5 ng/mL (after surgery)
  -  No rectal cancer
  -  No metastatic disease
  PATIENT CHARACTERISTICS:
  Age
  -  18 and over
  Performance status
  -  ECOG 0-1 OR
  -  Karnofsky 60-100%
  Life expectancy
  -  Not specified
  Hematopoietic
  -  Neutrophil count at least 2,000/mm3
  -  Platelet count at least 100,000/mm3
  Hepatic
  -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  -  SGOT and SGPT no greater than 5 times ULN
  Renal
  -  Creatinine no greater than 1.5 times ULN
  Cardiovascular
  -  No serious coronary disease
  Other
  -  Not pregnant
  -  Fertile patients must use effective contraception
  -  No concurrent infectious disease
  -  No other malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
  PRIOR CONCURRENT THERAPY:
  Biologic therapy
  -  No prior immunotherapy
  Chemotherapy
  -  No prior chemotherapy
  Endocrine therapy
  -  Not specified
  Radiotherapy
  -  No prior radiotherapy (before or after surgery)
  Surgery
  -  See Disease Characteristics
  Other
  -  No concurrent participation in another clinical trial

Relevance to patient case: not relevant